Dechra delivers ‘solid performance’

VET drugs company Dechra Pharmaceuticals said it had delivered a “solid” performance for the first six months of the financial year.
By The Newsroom
Published 25th Feb 2014, 09:19 BST

In the six months ended December 31 2013, reported underlying operating profit was £22.3m, including the benefit of the stock release of £1m.

This is an increase of 14.1 per cent at constant exchange rate on the same period the year before.

Hide Ad
Hide Ad

Ian Page, chief executive, said: “We continue to make progress in all four aspects of our strategy and we believe we are well positioned to continue to strengthen our position within the global animal health markets and to deliver future growth.”

The group owns the Dales manufacturing plant in Skipton.